Nektar Therapeutics (ITH0) Ratios
Nektar Therapeutics Ratios
DE:ITH0's free cash flow for Q2 2026 was $-75.88M. For the 2026 fiscal year, DE:ITH0's free cash flow was decreased by $-112.00K and operating cash flow was $-75.77M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 4.97 | 4.26 | 6.45 | 8.00 | 9.34 |
| Quick Ratio | 4.97 | 4.26 | 6.14 | 7.72 | 9.15 |
| Cash Ratio | 0.28 | 0.72 | 0.69 | 1.29 | 0.30 |
| Solvency Ratio | -0.86 | -0.47 | -1.00 | -1.03 | -1.16 |
| Operating Cash Flow Ratio | -3.89 | -2.86 | -3.76 | -4.46 | -4.84 |
| Short-Term Operating Cash Flow Coverage | -10.17 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 75.69M | $ 18.18M | $ 63.66M | $ 202.01M | $ 357.90M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.53 | 0.34 | 0.30 | 0.19 | 0.13 |
| Debt-to-Equity Ratio | 1.66 | 1.69 | 0.90 | 0.36 | 0.21 |
| Debt-to-Capital Ratio | 0.62 | 0.63 | 0.47 | 0.26 | 0.17 |
| Long-Term Debt-to-Capital Ratio | 0.41 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 3.12 | 5.00 | 3.04 | 1.94 | 1.64 |
| Debt Service Coverage Ratio | -2.93 | -3.08 | -9.59 | -11.31 | -9.77 |
| Interest Coverage Ratio | -4.99 | -3.74 | -5.42 | -8.31 | -9.43 |
| Debt to Market Cap | 0.12 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 10.38 | 9.53 | 11.30 | 12.86 | 15.59 |
| Net Debt to EBITDA | -0.98 | -0.67 | -0.34 | -0.13 | -0.26 |
| Profitability Margins | |||||
| Gross Profit Margin | 100.00% | 68.82% | 59.34% | 76.50% | 75.57% |
| EBIT Margin | -249.91% | -92.54% | -278.42% | -365.08% | -467.06% |
| EBITDA Margin | -248.05% | -88.08% | -269.75% | -351.82% | -453.18% |
| Operating Profit Margin | -236.77% | -106.88% | -152.49% | -260.97% | -437.76% |
| Pretax Profit Margin | -297.32% | -121.10% | -306.54% | -396.48% | -513.49% |
| Net Profit Margin | -297.07% | -120.86% | -306.31% | -399.98% | -514.03% |
| Continuous Operations Profit Margin | -297.07% | -120.86% | -306.31% | -399.98% | -514.03% |
| Net Income Per EBT | 99.92% | 99.80% | 99.93% | 100.88% | 100.11% |
| EBT Per EBIT | 125.57% | 113.31% | 201.02% | 151.93% | 117.30% |
| Return on Assets (ROA) | -58.51% | -39.15% | -69.36% | -51.82% | -46.89% |
| Return on Equity (ROE) | -182.65% | -195.86% | -210.75% | -100.43% | -77.09% |
| Return on Capital Employed (ROCE) | -57.64% | -43.39% | -39.63% | -37.40% | -43.23% |
| Return on Invested Capital (ROIC) | -52.82% | -40.02% | -37.52% | -36.34% | -42.51% |
| Return on Tangible Assets | -58.51% | -39.15% | -69.36% | -58.07% | -50.34% |
| Earnings Yield | -23.00% | -62.20% | -257.00% | -87.06% | -21.15% |
| Efficiency Ratios | |||||
| Receivables Turnover | 31.05 | 61.17 | 40.02 | 10.95 | 4.53 |
| Payables Turnover | 0.00 | 2.65 | 3.72 | 1.67 | 2.55 |
| Inventory Turnover | 0.00 | 0.00 | 2.28 | 1.13 | 1.58 |
| Fixed Asset Turnover | 11.04 | 8.32 | 2.44 | 1.07 | 0.57 |
| Asset Turnover | 0.20 | 0.32 | 0.23 | 0.13 | 0.09 |
| Working Capital Turnover Ratio | 0.27 | 0.41 | 0.24 | 0.15 | 0.12 |
| Cash Conversion Cycle | 11.76 | -131.54 | 71.41 | 138.29 | 169.31 |
| Days of Sales Outstanding | 11.76 | 5.97 | 9.12 | 33.32 | 80.56 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 160.38 | 323.95 | 231.65 |
| Days of Payables Outstanding | 0.00 | 137.50 | 98.09 | 218.98 | 142.89 |
| Operating Cycle | 11.76 | 5.97 | 169.50 | 357.28 | 312.21 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -12.36 | -12.82 | -15.21 | -24.37 | -33.77 |
| Free Cash Flow Per Share | -12.37 | -12.92 | -15.27 | -24.82 | -35.00 |
| Dividend Paid and CapEx Coverage Ratio | -1219.36 | -119.69 | -222.67 | -53.56 | -27.53 |
| Capital Expenditure Coverage Ratio | -1219.36 | -119.69 | -222.67 | -53.56 | -27.53 |
| Operating Cash Flow Coverage Ratio | -1.40 | -1.71 | -1.64 | -2.31 | -2.88 |
| Operating Cash Flow to Sales Ratio | -3.78 | -1.79 | -2.14 | -3.30 | -4.05 |
| Free Cash Flow Yield | -29.26% | -92.63% | -180.12% | -73.22% | -17.27% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -4.35 | -1.61 | -0.39 | -1.15 | -4.73 |
| Price-to-Sales (P/S) Ratio | 12.91 | 1.94 | 1.19 | 4.59 | 24.30 |
| Price-to-Book (P/B) Ratio | 7.94 | 3.15 | 0.82 | 1.15 | 3.64 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -3.42 | -1.08 | -0.56 | -1.37 | -5.79 |
| Price-to-Operating Cash Flow Ratio | -3.42 | -1.09 | -0.56 | -1.39 | -6.00 |
| Price-to-Earnings Growth (PEG) Ratio | -0.36 | 0.03 | 0.01 | 0.04 | -0.32 |
| Enterprise Value Multiple | -6.18 | -2.88 | -0.78 | -1.44 | -5.62 |
| Enterprise Value | 847.09M | 249.58M | 189.91M | 466.20M | 2.59B |
| EV to EBITDA | -6.18 | -2.88 | -0.78 | -1.44 | -5.62 |
| EV to Sales | 15.34 | 2.54 | 2.11 | 5.06 | 25.46 |
| EV to Free Cash Flow | -4.06 | -1.41 | -0.98 | -1.51 | -6.07 |
| EV to Operating Cash Flow | -4.06 | -1.42 | -0.99 | -1.53 | -6.29 |
| Tangible Book Value Per Share | 5.32 | 4.43 | 10.34 | 23.26 | 49.35 |
| Shareholders’ Equity Per Share | 5.32 | 4.43 | 10.34 | 29.39 | 55.61 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | -0.01 | -0.00 |
| Revenue Per Share | 3.27 | 7.18 | 7.11 | 7.38 | 8.34 |
| Net Income Per Share | -9.73 | -8.68 | -21.79 | -29.51 | -42.87 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.01 | 1.00 |
| Interest Burden | 1.19 | 1.31 | 1.10 | 1.09 | 1.10 |
| Research & Development to Revenue | 2.12 | 1.23 | 1.27 | 2.37 | 3.93 |
| SG&A to Revenue | 1.24 | 0.78 | 0.86 | 1.00 | 1.21 |
| Stock-Based Compensation to Revenue | 0.23 | 0.22 | 0.37 | 0.62 | 0.93 |
| Income Quality | 1.27 | 1.48 | 0.70 | 0.83 | 0.79 |
Currency in USD